DOCSLIB.ORG

Absinthin アブシンチン Acacetin アカセチン CAS RN

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Absinthin アブシンチン Acacetin アカセチン CAS RN Standards Catalog + Sep. 2021 Absinthin アブシンチン 天然物化学研究用 PHY（84170） 49871-41 10mg ￥70,000 Acacetin CAS RN®［480-44-4］ アカセチン 天然物化学研究用 C H O ...284.26 PHY（89482） 49060-00 20mg ￥51,000 16 12 5 Acesulfame K standard CAS RN®［55589-62-3］ アセスルファムK標準品 食品分析用 C H KNO S...201.24 関東化学（01690-96） 01690-96 >99.0%(HLC) 500mg ￥5,500 4 4 4 Acesulfame potassium standard CAS RN®［55589-62-3］ アセスルファム K標準品 C4H4KNO4S DES（C10010800） 250mg ￥12,000 2-Acetamido-5-nitrothiazole standard CAS RN®［140-40-9］ 2-アセトアミド-5-ニトロチアゾール標準品 C5H5N3O3S DES（C10012500） 100mg ￥28,000 Acetaminophen standard CAS RN®［103-90-2］ アセトアミノフェン標準品 食品分析用 C H NO ...151.16 関東化学（01602-96） 01602-96 >99.0%(HLC) 500mg ￥9,500 8 9 2 Acethylsulfamethoxazole-d4 standard CAS RN®［1215530-54-3］ アセチルスルファメトキサゾール-d4標準品 C12D4H9N3O4S DES（C10024051） 10mg ￥39,000 Acetic acid standard CAS RN®［64-19-7］ 酢酸標準品 食品分析用 CH COOH...60.05 DES（C10015500） 49861-56 1mL ￥5,800 3 Acetic acid-tert-butyl ester standard CAS RN®［540-88-5］ 酢酸-tert-ブチルエステル標準品 C6H12O2 DES（CA10015720） 1ml ￥12,000 Acetic acid-dimethylamide standard CAS RN®［127-19-5］ 酢酸ジメチルアミド標準品 C4H9NO DES（C10015900） 1mL ￥12,000 Standards Catalog + Sep. 2021 Acetic acid-2-ethoxyethyl ester standard CAS RN®［111-15-9］ 酢酸-2-エトキシエチルエステル標準品 C6H12O3 DES（C10016000） 1mL ￥9,500 Acetic acid-isobutyl ester standard CAS RN®［110-19-0］ 酢酸イソブチルエステル標準品 C6H12O2 DES（C10016100） 1mL ￥12,000 Acetic acid-isopropyl ester standard CAS RN®［108-21-4］ 酢酸イソプロピルエステル標準品 C5H10O2 DES（C10016200） 1ml ￥10,000 Acetic acid-linalyl ester standard CAS RN®［115-95-7］ 酢酸リナリルエステル標準品 C12H20O2 DES（C10016230） 250mg ￥12,000 Acetic acid-3-methylbutyl ester standard CAS RN®［123-92-2］ 酢酸-3-メチルブチルエステル標準品 C6H14O2 DES（C10016270） 250mg ￥12,000 Acetic acid-2-pentyl ester standard CAS RN®［626-38-0］ 酢酸-2-ペンチルエステル標準品 C7H14O2 DES（C10016400） 250mg ￥12,000 Acetic acid-phenyl ester standard CAS RN®［122-79-2］ 酢酸-フェニルエステル標準品 C8H8O2 DES（C10016450） 250mg ￥13,000 Acetic acid-n-propyl ester standard CAS RN®［109-60-4］ 酢酸-n-プロピルエステル標準品 C5H10O2 DES（C10016500） 1ml ￥8,800 Acetic acid-sec-butyl ester standard CAS RN®［105-46-4］ 酢酸-sec-ブチルエステル標準品 C6H12O2 DES（C10015710） 250mg ￥12,000 Acetonitrile standard CAS RN®［75-05-8］ アセトニトリル標準品 C2H3N DES（C10021000） 5ml ￥6,700 Standards Catalog + Sep. 2021 Acetovanillone CAS RN®［498-02-2］ アセトバニロン HOC6H3(OCH3)COCH3...16 天然物化学研究用 6.17 PHY（83252） 49869-00 100mg ￥40,000 1′-Acetoxychavicol acetate CAS RN®［52946-22-2］ 1′-アセトキシチャビコールアセテート 天然物化学研究用 C H O ...234.24 PHY（82458） 49060-01 10mg ￥66,000 13 14 4 15-Acetoxyscirpenol standard solution CAS RN®［2623-22-5］ 15-アセトキシシルペノール標準液 ｶﾋﾞ毒分析用 C H O ...324.36 B.P.（10002875） 49160-61 1mL ￥98,000 17 24 6 「毒素等を試験研究用に使用す ることを確認する証」が必要で す。50mg/L アセトニトリル溶 液 Acetoxyvalerenic acid CAS RN®［84638-55-1］ アセトキシバレレン酸 天然物化学研究用 C H O ...292.36 PHY（89151） 49060-02 10mg ￥65,000 17 24 4 2′-Acetylacteoside CAS RN®［94492-24-7］ 2′-アセチルアクテオシド C31H38O16...666.62 天然物化学研究用 PHY（83476） 49870-46 10mg ￥66,000 6-Acetylacteoside CAS RN®［441769-43-3］ 6-アセチルアクテオシド 天然物化学研究用 C H O ...666.62 PHY（89554） 49060-03 10mg ￥70,000 31 38 16 2-Acetylamino-5-nitrothiazole standard CAS RN®［140-40-9］ 2-アセチルアミノ-5-ニトロチアゾール標準品 食品分析用 C H N O S...187.17 関東化学（01929-96） 01929-96 >98.0%(HLC) 500mg ￥10,000 5 5 3 3 3-O-Acetyl 11-keto-β-boswellic acid CAS RN®［67416-61-9］ 3-Ｏ-アセチル-11-ケト-β-ボスウェル酸 天然物化学研究用 C H O ...512.71 PHY（89153） 49060-05 10mg ￥81,000 32 48 5 3-O-Acetyl α-boswellic acid CAS RN®［89913-60-0］ 3-Ｏ-アセチルα-ボスウェル酸 天然物化学研究用 C H O ...498.73 PHY（89555） 49060-06 10mg ￥105,000 32 50 4 Standards Catalog + Sep. 2021 3-O-Acetyl β-boswellic acid CAS RN®［5968-70-7］ 3-Ｏ-アセチルβ-ボスウェル酸 天然物化学研究用 C H O ...498.73 PHY（89152） 49060-04 10mg ￥85,000 32 50 4 3-O-Acetyl 9,11-dehydro β-boswellic acid CAS RN®［122651-20-1］ 3-Ｏ-アセチル9,11-デヒドロβ-ボスウェル酸 天然物化学研究用 C H O ...496.71 PHY（83240） 49868-93 5mg ￥86,000 32 48 4 13 C17-15-Acetyldeoxynivalenol standard solution １３ C１７-15-アセチルデオキシニバレノール標準液 「毒素等を試験研究用に使用す ｶﾋﾞ毒分析用 ることを確認する証」が必要で B.P.（10002840） 49161-23 1.2mL ☆ す。10μg/mL アセトニトリル 溶液 13 C17-3-Acetyldeoxynivalenol standard solution １３ C１７-3-アセチルデオキシニバレノール標準液 13 C17H22O7...355.22 ｶﾋﾞ毒分析用 「毒素等を試験研究用に使用す B.P.（10002811） 49150-62 1.2mL ☆ ることを確認する証」が必要で す。25mg/L アセトニトリル溶 液 15-Acetyldeoxynivalenol standard CAS RN®［88337-96-6］ 15-アセチルデオキシニバレノール標準品 ｶﾋﾞ毒分析用 C H O ...338.35 B.P.（10000322） 49150-75 10mg ￥130,000 17 22 7 「毒素等を試験研究用に使用す B.P.（10000305） 49150-74 5mg ￥73,000 ることを確認する証」が必要で す。 15-Acetyldeoxynivalenol standard solution CAS RN®［88337-96-6］ 15-アセチルデオキシニバレノール標準液 ｶﾋﾞ毒分析用 C H O ...338.35 B.P.（10000338） 49150-11 5mL ￥65,000 17 22 7 「毒素等を試験研究用に使用す B.P.（10003650） 49150-33 1mL ￥38,000 ることを確認する証」が必要で す。100mg/L アセトニトリル溶 液 3-Acetyldeoxynivalenol standard CAS RN®［50722-38-8］ 3-アセチルデオキシニバレノール標準品 ｶﾋﾞ毒分析用 C H O ...338.35 B.P.（10000319） 49150-73 10mg ￥130,000 17 22 7 「毒素等を試験研究用に使用す B.P.（10000302） 49150-72 5mg ￥73,000 ることを確認する証」が必要で す。 Standards Catalog + Sep. 2021 3-Acetyldeoxynivalenol standard solution CAS RN®［50722-38-8］ 3-アセチルデオキシニバレノール標準液 ｶﾋﾞ毒分析用 C H O ...338.35 B.P.（10000337） 49150-10 5mL ￥65,000 17 22 7 「毒素等を試験研究用に使用す B.P.（10003649） 49150-32 1mL ￥38,000 ることを確認する証」が必要で す。100mg/L アセトニトリル溶 液 Acetyleugenol CAS RN®［93-28-7］ アセチルオイゲノール C12H14O3...206.23 天然物化学研究用 PHY（82460） 49060-08 100mg ￥40,000 2-Acetylfuran standard CAS RN®［1192-62-7］ 2-アセチルフラン標準品 C6H6O2 DES（C10023800） 1mL ￥12,000 8-Acetylshanzhiside methyl ester CAS RN®［57420-46-9］ 8-アセチルシャンジシドメチルエステル 天然物化学研究用 C H O ...448.41 PHY（82461） 49060-09 10mg ￥80,000 19 28 12 Acid Blue 1 standard CAS RN®［129-17-9］ アシッドブルー1標準品 C27H31N2NaO6S2 DES（C10028100） 100mg ￥27,000 Acid Blue 3 calcium standard CAS RN®［3536-49-0］ アシッドブルー3 カルシウム塩標準品 C27H31N2O7S2･1/2Ｃａ DES（C10028130） 100mg ￥26,000 Acid mordant Black 1 (technical) standard CAS RN®［3618-58-4］ アシッドモーダントブラック1標準品 C20H12N3NaO7S DES（C10028500） 100mg ￥15,000 Acid Red 73 standard CAS RN®［5413-75-2］ アシッドレッド73標準品 C22H14N4Na2O7S2 DES（C10028830） 100mg ￥12,000 Acid Violet 9 standard CAS RN®［6252-76-2］ アシッドバイオレット9標準品 C34H25N2NaO6S DES（C10028870） 100mg ￥27,000 Standards Catalog + Sep. 2021 Acid Yellow 36 standard CAS RN®［587-98-4］ アシッドイエロー36標準品 C18H14N3NaO3S DES（C10029500） 100mg ￥43,000 Acid Yellow 23 Aluminium lake standard CAS RN®［12225-21-7］ アシッドイエロー23アルミニウム塩標準品 C16H9Al3N4O9S2 DES（E10029060） 100mg ￥39,000 trans-Aconitic acid CAS RN®［4023-65-8］ ｔｒａｎｓ-アコニット酸 C6H6O6...174.10 天然物化学研究用 PHY（82257） 49060-11 100mg ￥40,000 Aconitine CAS RN®［302-27-2］ アコニチン 天然物化学研究用 C H NO ...645.73 PHY（89376） 49060-12 20mg ￥51,000 34 47 11 Acrylamide standard CAS RN®［79-06-1］ アクリルアミド標準品 食品分析用 CH :CHCONH ...71.07 関東化学（01078-96） 01078-96 >99.0%(HLC) 500mg ￥5,800 2 2 Acrylamide standard CAS RN®［79-06-1］ アクリルアミド標準品 C3H5NO DES（C10045300） 250mg ￥12,000 Acrylic acid butyl ester standard CAS RN®［141-32-2］ アクリル酸ブチルエステル標準品 C7H12O2 DES（CA10045350） 1ml ￥9,500 Acrylic acid ethyl ester standard CAS RN®［140-88-5］ アクリル酸エチルエステル標準品 C5H8O2 DES（CA10045380） 1ml ￥12,000 Acrylic acid-2-ethylhexyl ester standard CAS RN®［103-11-7］ アクリル酸-2-エチルヘキシルエステル標準品 C11H20O2 DES（CA10045390） 1ml ￥9,500 Acrylic acid methyl ester standard CAS RN®［96-33-3］ アクリル酸メチルエステル標準品 C4H6O2 DES（CA10045400） 1ml ￥12,000 Standards Catalog + Sep. 2021 Actein CAS RN®［18642-44-9］ アクテイン C37H56O11...676.83 天然物化学研究用 PHY（89154） 49060-13 10mg ￥80,000 Acyclovir standard CAS RN®［59277-89-3］ アシクロビルナトリウム標準品 C8H10N5NaO3 DES（C10045600） 100mg ￥30,000 Adipic acid standard CAS RN®［124-04-9］ アジピン酸標準品 C6H10O4 DES（C10045900） 250mg ￥12,000 Adipic acid, bis-n-butyl ester standard CAS RN®［105-99-7］ アジピン酸ジ-n-ブチルエステル標準品 C14H26O4 DES（C10046100） 250mg ￥14,000 Adipic acid, bis-2-ethylhexyl ester standard CAS RN®［103-23-1］ アジピン酸ビス-2-エチルヘキシルエステル標準品 C22H42O4 DES（C10046000） 250mg ￥20,000 Adipic acid, bis-2-ethylhexyl ester-d4 standard アジピン酸ジ-2-エチルヘキシルエステル-d4標準品 C22H38D4O4 DES（C10046010） 10mg ☆ Adipic acid-dimethyl ester standard CAS RN®［627-93-0］ アジピン酸ジメチルエステル標準品 C8H14O4 DES（C10046200） 250mg ￥13,000 Aegeline CAS RN®［456-12-2］ アエゲリン C18H19NO3...297.34 天然物化学研究用 PHY（83467） 49870-47 10mg ￥60,000 13 C17-Aflatoxin B1 standard solution １３ C１７-アフラトキシンB１標準液 13 C17H12O6...329.14 ｶﾋﾞ毒分析用 「毒素等を試験研究用に使用す B.P.（10002818） 49160-24 1.2mL ☆ ることを確認する証」が必要で す。0.5mg/L アセトニトリル溶 液 Standards Catalog + Sep. 2021 13 C17-Aflatoxin B2 standard solution １３ C１７-アフラトキシンB２標準液 13 C17H14O6...331.16 ｶﾋﾞ毒分析用 「毒素等を試験研究用に使用す B.P.（10002819） 49160-43 1.2mL ☆ ることを確認する証」が必要で す。0.5mg/L アセトニトリル溶 液 ® Aflatoxin B1 standard CAS RN ［1162-65-8］ アフラトキシンB１標準品 ｶﾋﾞ毒分析用 C17H12O6...312.27 B.P.（10000311） 49160-26 5mg ￥70,000 「毒素等を試験研究用に使用す ることを確認する証」が必要で す。 ® Aflatoxin B1 standard solution CAS RN ［1162-65-8］ アフラトキシンB１標準液 ｶﾋﾞ毒分析用 C17H12O6...312.27 B.P.（10000340） 49150-18 5mL ￥50,000 「毒素等を試験研究用に使用す B.P.（10003652） 49150-34 1mL ￥36,000 ることを確認する証」が必要で す。2mg/L アセトニトリル溶液 ® Aflatoxin B2 standard CAS RN ［7220-81-7］ アフラトキシンB２標準品 ｶﾋﾞ毒分析用 C17H14O6...314.28 B.P.（10000312） 49160-27 5mg ￥100,000 「毒素等を試験研究用に使用す ることを確認する証」が必要で す。 ® Aflatoxin B2 standard solution CAS RN ［7220-81-7］ アフラトキシンB２標準液 ｶﾋﾞ毒分析用 C17H14O6...314.28 B.P.（10000341） 49150-19 5mL ￥50,000 「毒素等を試験研究用に使用す B.P.（10003653） 49150-35 1mL ￥36,000 ることを確認する証」が必要で す。0.5mg/L アセトニトリル溶 液 13 C17-Aflatoxin G1 standard solution １３ C１７-アフラトキシンG１標準液 13 C17H12O7...345.14 ｶﾋﾞ毒分析用 「毒素等を試験研究用に使用す B.P.（10002820） 49160-44 1.2mL ☆ ることを確認する証」が必要で す。0.5mg/L アセトニトリル溶 液 Standards Catalog + Sep.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 Mccleary Et Al
    US 200301 05159A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 McCleary et al. (43) Pub. Date: Jun. 5, 2003 (54) KAVALACTONE COMPOSITIONS AND Publication Classification METHODS OF USE (51) Int. Cl." ....................... A61K 31/35; A61K 31/366; (76) Inventors: Joel McCleary, The Plains, VA (US); A61K 35/78; A61K 31/16 Peter S. Staats, Towson, MD (US) (52) U.S. Cl. ........................... 514/460; 514/625; 424/760 Correspondence Address: FISH & RICHARDSON PC 225 FRANKLIN ST BOSTON, MA 02110 (US) (57) ABSTRACT (21) Appl. No.: 10/214,624 (22) Filed: Aug. 8, 2002 This invention relates tO kavalactone-containing composi tions, and more particularly to compositions having com Related U.S. Application Data pounds derived from kavalactones and from capsaicinoids. The compositions are useful in modulating pain, and thus (60) Provisional application No. 60/311,437, filed on Aug. can be used to mediate, or eliminate, Sensations of pain, 10, 2001. thereby providing pain relief and reduction. US 2003/0105159 A1 Jun. 5, 2003 KAVALACTONE COMPOSITIONS AND METHODS 0006. In one embodiment, the invention relates to an OF USE analgesic topical composition having: (a) a kavalactone; (b) capsaicinoid or Synthetic derivatives thereof; and (c) a CROSS-REFERENCE TO RELATED pharmaceutically acceptable carrier; wherein the weight APPLICATIONS ratio of(a):(b) is from 5000:1 to 1:2 (e.g., 800:1 to 1:1; 500:1 to 5:1). In other aspects, the composition includes an effec 0001. This application claims benefit of U.S. application tive amount of kavalactones, active kavalactones, or capsai Ser.
    [Show full text]
  • Yangonin Blocks Tumor Necrosis Factor-Α–Induced Nuclear Factor-Κb–Dependent Transcription by Inhibiting the Transactivation Potential of the Rela/P65 Subunit
    J Pharmacol Sci 118, 447 – 454 (2012) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Full Paper Yangonin Blocks Tumor Necrosis Factor-α–Induced Nuclear Factor-κB–Dependent Transcription by Inhibiting the Transactivation Potential of the RelA/p65 Subunit Juan Ma1,†, He Liang1,†, Hong Ri Jin2, Nguyen Tien Dat3, Shan Yu Zhang1, Ying Zi Jiang1, Ji Xing Nan1, Donghao Li1, Xue Wu1, Jung Joon Lee1,2,*a, and Xuejun Jin1,*b 1Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Yanbian University, Ministry of Education, Yanji Jilin 133002, China 2Center for Molecular Cancer Research, Korea Research Institute of Bioscience and Biotechnology, Ochang, Chungbuk 363-883, Republic of Korea 3Institute of Marine Biochemistry, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Hanoi, Vietnam Received November 13, 2011; Accepted January 23, 2012 Abstract. The nuclear factor-κB (NF-κB) transcription factors control many physiological pro- cesses including inflammation, immunity, and apoptosis. In our search for NF-κB inhibitors from natural resources, we identified yangonin from Piper methysticum as an inhibitor of NF-κB activa- tion. In the present study, we demonstrate that yangonin potently inhibits NF-κB activation through suppression of the transcriptional activity of the RelA/p65 subunit of NF-κB. This compound sig- nificantly inhibited the induced expression of the NF-κB-reporter gene. However, this compound did not interfere with tumor necrosis factor-α (TNF-α)-induced inhibitor of κBα (IκBα) degrada- tion, p65 nuclear translocation, and DNA-binding activity of NF-κB. Further analysis revealed that yangonin inhibited not only the induced NF-κB activation by overexpression of RelA/p65, but also transactivation activity of RelA/p65.
    [Show full text]
  • Toxicity Equivalence Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER
    JOINT FAO/WHO Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER Cover photograph: © FAOemergencies JOINT FAO/WHO Toxicity equivalence factors for marine biotoxins associated with bivalve molluscs TECHNICAL PAPER FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS WORLD HEALTH ORGANIZATION ROME, 2016 Recommended citation: FAO/WHO. 2016. Technical paper on Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs. Rome. 108 pp. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) or of the World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these are or have been endorsed or recommended by FAO or WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by FAO and WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall FAO and WHO be liable for damages arising from its use.
    [Show full text]
  • Herbal Insomnia Medications That Target Gabaergic Systems: a Review of the Psychopharmacological Evidence
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2014, 12, 000-000 1 Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence Yuan Shia, Jing-Wen Donga, Jiang-He Zhaob, Li-Na Tanga and Jian-Jun Zhanga,* aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China; bDepartment of Pharmacology, School of Marine, Shandong University, Weihai, P.R. China Abstract: Insomnia is a common sleep disorder which is prevalent in women and the elderly. Current insomnia drugs mainly target the -aminobutyric acid (GABA) receptor, melatonin receptor, histamine receptor, orexin, and serotonin receptor. GABAA receptor modulators are ordinarily used to manage insomnia, but they are known to affect sleep maintenance, including residual effects, tolerance, and dependence. In an effort to discover new drugs that relieve insomnia symptoms while avoiding side effects, numerous studies focusing on the neurotransmitter GABA and herbal medicines have been conducted. Traditional herbal medicines, such as Piper methysticum and the seed of Zizyphus jujuba Mill var. spinosa, have been widely reported to improve sleep and other mental disorders. These herbal medicines have been applied for many years in folk medicine, and extracts of these medicines have been used to study their pharmacological actions and mechanisms. Although effective and relatively safe, natural plant products have some side effects, such as hepatotoxicity and skin reactions effects of Piper methysticum. In addition, there are insufficient evidences to certify the safety of most traditional herbal medicine. In this review, we provide an overview of the current state of knowledge regarding a variety of natural plant products that are commonly used to treat insomnia to facilitate future studies.
    [Show full text]
  • Herbal Medicines in Pregnancy and Lactation : an Evidence-Based
    00 Prelims 1410 10/25/05 2:13 PM Page i Herbal Medicines in Pregnancy and Lactation An Evidence-Based Approach Edward Mills DPh MSc (Oxon) Director, Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Jean-Jacques Duguoa MSc (cand.) ND Naturopathic Doctor Toronto Western Hospital Assistant Professor Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Dan Perri BScPharm MD MSc Clinical Pharmacology Fellow University of Toronto Toronto, Ontario, Canada Gideon Koren MD FACMT FRCP Director of Motherisk Professor of Medicine, Pediatrics and Pharmacology University of Toronto Toronto, Ontario, Canada With a contribution from Paul Richard Saunders PhD ND DHANP 00 Prelims 1410 10/25/05 2:13 PM Page ii © 2006 Taylor & Francis Medical, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2006 by Taylor & Francis Medical, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN Tel.: ϩ44 (0)20 7017 6000 Fax.: ϩ44 (0)20 7017 6699 E-mail: [email protected] Website: www.tandf.co.uk/medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP.
    [Show full text]
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Current Perspectives in Herbal and Conventional Drug Interactions
    Surana et al. Future Journal of Pharmaceutical Sciences (2021) 7:103 Future Journal of https://doi.org/10.1186/s43094-021-00256-w Pharmaceutical Sciences REVIEW Open Access Current perspectives in herbal and conventional drug interactions based on clinical manifestations Ajaykumar Rikhabchand Surana* , Shivam Puranmal Agrawal, Manoj Ramesh Kumbhare and Snehal Balu Gaikwad Abstract Background: Herbs are an important source of pharmaceuticals. Herbs are traditionally used by millions of peoples for medicine, food and drink in developed and developing nations considering that they are safe. But, interaction of herbs with other medicines may cause serious adverse effects or reduces their efficacy. The demand for “alternative” medicines has been increased significantly, which include medicine derived from plant or herbal origin. The objective of this review article mainly focuses on drug interactions of commonly used herbs along with possible mechanisms. The method adopted for this review is searching of herb-drug interactions in online database. Main text: Herb-drug interaction leads to pharmacological modification. The drug use along with herbs may show pharmacodynamic and pharmacokinetic interactions. Pharmacokinetic interaction causes alteration in absorption, distribution, metabolism and elimination. Similarly, pharmacodynamic interaction causes additive or synergistic or antagonist effect on the drugs or vice versa. Researchers had demonstrated that herbs show the toxicities and drug interactions like other pharmacologically active compounds. There is lack of knowledge amongst physician, pharmacist and consumers related to pharmacological action and mechanism of herb-drug interaction. This review article focuses on the herb-drug interaction of danshen (Salvia miltiorrhiza), Echinacea (Echinacea purpurea), garlic (Allium sativum), ginkgo (Ginkgo biloba), goldenseal (Hydrastis canadensis), green tea (Camellia sinensis), kava (Piper methysticum), liquorice (Glycyrrhiza glabra), milk thistle (Silybum marianum) and St.
    [Show full text]
  • Kava As a Pharmacotherapy of Anxiety
    l ch cina em di is Rivers et al., Med chem 2016, 6:2 e tr M y Medicinal chemistry DOI: 10.4172/2161-0444.1000329 ISSN: 2161-0444 Review Article Open Access Kava as a Pharmacotherapy of Anxiety Disorders: Promises and Concerns Zachary Rivers1, Chengguo Xing2 and Sreekanth Narayanapillai2* 1College of Pharmacy, University of Minnesota, 308 Harvard St SE, Minneapolis, MN 55455, USA 2Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 2231 6th St SE, Minneapolis, MN 55455, USA Abstract Current standard pharmacotherapies for anxiety management come with a host of side-effects that may deter the patients from utilizing them. Kava, a traditional beverage from the South Pacific region, has been used as a natural medicine for centuries and has been hypothesized to contain anxiolytic properties. There are a few well-designed, randomly controlled trials that have evaluated the effectiveness of kava or its constituents against anxiety disorders. They have generally shown kava to be effective in managing the disease. However, there has been a serious concern about the hepatotoxic risk of kava, which greatly limits its anxiolytic development and application. This review attempts to summarize the recent anxiolytic trials using kava, the associated hepatotoxicity risks, the potential responsible chemicals for these two activities, and the mechanisms of action. Overall, kava has a great potential to be developed as a natural anxiolytic agent through a systematic approach, but the present form should be used with caution. Keywords: Anxiety disorders; Muscle tension; Insomnia; Treatment conditions than a prescription drug. Kava is one such natural product that has been used in the treatment of anxiety disorders.
    [Show full text]
  • Download PDF Flyer
    REVIEWS IN PHARMACEUTICAL & BIOMEDICAL ANALYSIS Editors: Constantinos K. Zacharis and Paraskevas D. Tzanavaras eBooks End User License Agreement Please read this license agreement carefully before using this eBook. Your use of this eBook/chapter constitutes your agreement to the terms and conditions set forth in this License Agreement. Bentham Science Publishers agrees to grant the user of this eBook/chapter, a non-exclusive, nontransferable license to download and use this eBook/chapter under the following terms and conditions: 1. This eBook/chapter may be downloaded and used by one user on one computer. The user may make one back-up copy of this publication to avoid losing it. The user may not give copies of this publication to others, or make it available for others to copy or download. For a multi-user license contact [email protected] 2. All rights reserved: All content in this publication is copyrighted and Bentham Science Publishers own the copyright. You may not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit any of this publication’s content, in any form by any means, in whole or in part, without the prior written permission from Bentham Science Publishers. 3. The user may print one or more copies/pages of this eBook/chapter for their personal use. The user may not print pages from this eBook/chapter or the entire printed eBook/chapter for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained from the publisher for such requirements.
    [Show full text]
  • Author's Personal Copy
    Author's personal copy Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This chapter was originally published in the book Encyclopedia of Toxicology. The copy attached is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research, and educational use. This includes without limitation use in instruction at your institution, distribution to specific colleagues, and providing a copy to your institution's administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier’s permissions site at: http://www.elsevier.com/locate/permissionusematerial From Hambright, K.D., Zamor, R.M., Easton, J.D., Allison, B., 2014. Algae. In: Wexler, P. (Ed.), Encyclopedia of Toxicology, 3rd edition vol 1. Elsevier Inc., Academic Press, pp. 130–141. ISBN: 9780123864543 Copyright © 2014 Elsevier, Inc. unless otherwise stated. All rights reserved. Academic Press Author's personal copy Algae KD Hambright and RM Zamor, Plankton Ecology and Limnology Laboratory, University of Oklahoma Biological Station, and Program in Ecology and Evolutionary Biology, University of Oklahoma, Norman, OK, USA JD Easton and B Allison, Plankton Ecology and Limnology Laboratory, University of Oklahoma Biological Station, University of Oklahoma, Kingston, OK, USA Ó 2014 Elsevier Inc. All rights reserved. This article is a revision of the previous edition article by Keiko Okamoto and Lora E. Fleming, volume 1, pp 68–76, Ó 2005, Elsevier Inc.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative Chemical Dosage (+)-BORNYL-ISOVALERATE -- (-)-DICENTRINE LD50=187 1,8-CINEOLE -- 2-METHYLBUT-3-ENE-2-OL -- 6-GINGEROL -- 6-SHOGAOL -- ACYLSPINOSIN -- ADENOSINE -- AKUAMMIDINE -- ALPHA-PINENE -- ALPHA-TERPINEOL -- AMYL-BUTYRATE -- AMYLASE -- ANEMONIN -- ANGELIC-ACID -- ANGELICIN ED=20-80 ANISATIN 0.03 mg/kg ANNOMONTINE -- APIGENIN 30-100 mg/kg ARECOLINE 1 mg/kg ASARONE -- ASCARIDOLE -- ATHEROSPERMINE -- BAICALIN -- BALDRINAL -- BENZALDEHYDE -- BENZYL-ALCOHOL -- Chemical Dosage BERBERASTINE -- BERBERINE -- BERGENIN -- BETA-AMYRIN-PALMITATE -- BETA-EUDESMOL -- BETA-PHENYLETHANOL -- BETA-RESERCYCLIC-ACID -- BORNEOL -- BORNYL-ACETATE -- BOSWELLIC-ACID 20-55 mg/kg ipr rat BRAHMINOSIDE -- BRAHMOSIDE -- BULBOCAPNINE -- BUTYL-PHTHALIDE -- CAFFEIC-ACID 500 mg CANNABIDIOLIC-ACID -- CANNABINOL ED=200 CARPACIN -- CARVONE -- CARYOPHYLLENE -- CHELIDONINE -- CHIKUSETSUSAPONIN -- CINNAMALDEHYDE -- CITRAL ED 1-32 mg/kg CITRAL 1 mg/kg CITRONELLAL ED=1 mg/kg CITRONELLOL -- 2 Chemical Dosage CODEINE -- COLUBRIN -- COLUBRINOSIDE -- CORYDINE -- CORYNANTHEINE -- COUMARIN -- CRYOGENINE -- CRYPTOCARYALACTONE 250 mg/kg CUMINALDEHYDE -- CUSSONOSIDE-A -- CYCLOSTACHINE-A -- DAIGREMONTIANIN -- DELTA-9-THC 10 mg/orl/man/day DESERPIDINE -- DESMETHOXYANGONIN 200 mg/kg ipr DIAZEPAM 40-200 ug/lg/3-4x/day DICENTRINE LD50=187 DIDROVALTRATUM -- DIHYDROKAWAIN -- DIHYDROMETHYSTICIN 60 mg/kg ipr DIHYDROVALTRATE -- DILLAPIOL ED50=1.57 DIMETHOXYALLYLBENZENE -- DIMETHYLVINYLCARBINOL -- DIPENTENE
    [Show full text]